Aspire Biopharma Holdings (ASBP) Net Cash Flow (2021 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Net Cash Flow came in at $6.3 million in Q2 2026, up 653.37% year-over-year from $837586.8 in Q2 2025, and up 30.02% quarter-over-quarter from $4.9 million in Q1 2026.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Net Cash Flow (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Net Cash Flow for 6 consecutive years, with $6.3 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Cash Flow rose 653.37% year-over-year to $6.3 million in Q2 2026; TTM through Jun 2026 was $12.0 million, a 6308.92% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, down 92.74% from the prior year.
- Net Cash Flow was $6.3 million for Q2 2026 at Aspire Biopharma Holdings, up from $4.9 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $6.3 million in Q2 2026 and troughed at -$1.1 million in Q2 2025.
- A 5-year average of $675331.2 and a median of -$20295.5 in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 56973.59% in 2025, down 7216.14% in 2025.
- Over 5 years, Net Cash Flow stood at -$35870.0 in 2022, then jumped by 99.22% to -$280.0 in 2023, then slumped by 4510.0% to -$12908.0 in 2024, then slumped by 7216.14% to -$944367.0 in 2025, then soared by 768.18% to $6.3 million in 2026.
- The last three Net Cash Flow figures came in at $6.3 million (Q2 2026), $4.9 million (Q1 2026), and -$944367.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -183.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -170.75 Mn |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 | 6.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.31 Mn |
| Mar 31, 2026 | 4.85 Mn |
| Dec 31, 2025 | -944,367.00 |
| Sep 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | -12,908.00 |
| Sep 30, 2024 | -3,063.00 |
| Jun 30, 2024 | -27,683.00 |
| Mar 31, 2024 | 36,113.00 |
| Dec 31, 2023 | -280.00 |
| Sep 30, 2023 | -124,921.00 |
| Jun 30, 2023 | -189,951.00 |
| Mar 31, 2023 | -182,107.00 |
| Dec 31, 2022 | -35,870.00 |
| Sep 30, 2022 | -46,622.00 |
| Jun 30, 2022 | -38,371.00 |
| Mar 31, 2022 | 618,122.00 |
| Jun 30, 2021 | 135,040.00 |